Loss of p27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma

Oncology

Volumn 58, Issue 2, 2000, Pages 152-158

  Shamma, Awad ^a   Doki, Yuichiro ^a   Tsujinaka, Toshimasa ^a   Shiozaki, Hitoshi ^a   Inoue, Masatoshi ^a   Yano, Masahiko ^a   Kawanishi, Kensyu ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Esophageal; Immunohistochemistry; P16(INK4); P27(KIP1); Prognosis; Squamous cell carcinoma

Indexed keywords

ANTIGEN; CYCLINE; PROTEIN P16; PROTEIN P27;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TUMOR DIFFERENTIATION;

EID: 0033998106     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012092     Document Type: Article

References (27)

1. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come to age. Cell 1994;79:573-582.
2. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-1163.
3. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
4. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27 (Kip1).Cell 1996;85:721-732.
5. Mori T, Miura K, Aoki T, Nishihara T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/ cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-3397.
6. Muzeau F, Flejou JF, Thomas G, Hamelin R: Loss of heterozygosity on chromosome 9 and pi6 (MTS1, CDKN2) gene mutation in esophageal cancers. Int J Cancer 1997;72:27-30.
7. Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Inoue M, Yano M, Kimura Y, Yamamoto M, Monden M: Effect of cyclin D1 and associated proteins on proliferation of esophageal squamous cell carcinoma. Int J Oncol 1998;13:455-460.
8. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S: Molecular analysis of the cyclin-dependent kinase inhibitor p27/ Kip1 in human malignancies. Cancer Res 1995;55:2266-2269.
9. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997;3:231-234.
10. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell cycle inhibitor p27KIP1 protein: Prognostic implication in primary breast cancer. Nature Met 1997;3:227-230.
11. Esposito V, Baldi A, De-Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57: 3381-3385.
12. Singh SP, Lipman J, Goldman H, Ellis FH, Aiseman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-1735.
13. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nature Med 1997;3: 593.
14. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, Dekernion JB, Loda M, Reiter RE: Low p27 expression predicts poor prognosis in patients with prostate cancer. J Urol 1998;159:941-945.
15. Pagano M, Tam SW, Theodoras AM, Romero PB, Sal GD, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
16. International Union against Cancer: TNM Classification of Malignant Tumors, revised ed. New York, Springer, 1987.
17. De Meester TR, Barlow AP: Surgery and current management for cancer of the esophagus. Curr Probl Cancer 1988;12:243-328.
18. Earlam R, Cunha-Melo JR: Esophageal squamous cell carcinoma: A critical review of surgery. Br J Surg 1980;67:381-390.
19. Naka T, Kobayashi M, Ashida K, Toyota N, Kaneko T, Kaibara N: Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. Int J Oncol 1998;12:1111-1116.
20. Shimada M, Yanagisawa A, Kato W, Inoue M, Shiozaki H, Monden M, Nakamura Y: Genetic mechanisms in esophageal carcinogenesis: Frequent deletion of 3p and 17p in premalignant lesions. Genes Chromosomes Cancer 1996;15: 165-169.
21. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, Kitajima M: Altered P16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 1997;3:2229-2236.
22. Sgambato A, Zhang YJ, Ciaparrone M, Soh JW, Cittadini A, Santella RM, Weinstein IB: Overexpression of p27Kip1 inhibits the cell growth of both normal and transformed human mammary epithelial cells. Cancer Res 1998;58: 3448-3454.
23. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P: Promoting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997;57: 5441-5445.
24. Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK: Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 1996;133:391-403.
25. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingoland JM, Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27KIP1 on resistance of tumor cells to anticancer agents. Nature Med 1996;2:1204-1210.
26. Anayama T, Furihata M, Ishikawa T, Ohtsuki Y, Ogoshi S: Positive correlation between p27KIP1 expression and progression of human esophageal squamous cell carcinoma. Int J Cancer 1998;79:439-443.
27. Kiichiro T, Yukiko K, Jun-Ya K: Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999; 398:160-165.